(Q28217407)

English

Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group

scientific article (publication date: 2 May 2006)

In more languages

Statements

scholarly article

0 references

1 reference

26 October 2020

systematic review

1 reference

PubMed publication ID

Non-hormonal systemic therapy in men with hormone-refractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-based Care's Genitourinary Cancer Disease Site Group (English)

0 references

prostate neoplasm

1 reference

26 October 2020

evidence-based medicine

1 reference

2 October 2020

antineoplastic resistance

1 reference

26 October 2020

systematic review

1 reference

based on heuristic

inferred from title

systemic therapy

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

author name string

Eric Winquist

1

0 references

Tricia Waldron

2

0 references

Scott Berry

3

0 references

D Scott Ernst

4

0 references

Sébastien Hotte

5

0 references

Himu Lukka

6

0 references

language of work or name

0 references

publication date

2 May 2006

4 references

3 April 2019

20 August 2019

2 October 2020

26 October 2020

4 references

3 April 2019

20 August 2019

2 October 2020

26 October 2020

6

0 references

1

0 references

112

0 references

copyright license

Creative Commons Attribution 2.0 Generic

4 references

Europe PubMed Central

3 April 2019

Europe PubMed Central

20 August 2019

Europe PubMed Central

2 October 2020

Europe PubMed Central

26 October 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

7 April 2017

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

7 April 2017

Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Management of hormone refractory prostate cancer: current standards and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Weekly chemotherapy in advanced prostatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

A comparison of hydroxyurea, methyl-chloroethyl-cyclohexy-nitrosourea and cyclophosphamide in patients with advanced carcinoma of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Hormone-refractory metastatic prostatic cancer treated with methotrexate, cyclophosphamide plus adriamycin, cis-platinum plus 5-fluorouracil plus cyclophosphamide. National Prostatic Cancer Project randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Comparison of Megace, Stilphostrol, Megace plus DES, or streptozotocin in metastatic prostatic cancer in patients with hormonal failure and prior radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Comparison of Procarbazine, Imidazole-Carboxamide and Cyclophosphamide in Relapsing Patients with Advanced Carcinoma of the Prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer. A randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

Evaluation of melphalan, ICRF-159, and hydroxyurea in metastatic prostate cancer: a preliminary report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

A Comparison of Estramustine Phosphate and Streptozotocin in Patients with Advanced Prostatic Carcinoma Who Have Had Extensive Irradiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

29 September 2017

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Skeletal complications of malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy versus chloroethyl-cyclohexy-nitrosourea in the treatment of metastatic prostatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Sequential hormonal therapy and sequential hormonal and chemotherapy for advanced prostatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Anal submucosal injection: a new route for drug administration in pelvic malignancies. V. Advanced prostatic cancer: results of methotrexate treatment using the anal route--preliminary study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

High-dose Medroxyprogesterone Acetate versus Estramustine in Therapy-resistant Prostatic Cancer: A Randomised Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

Adriamycin (NSC-123127) versus 5-fluorouracil (NSC-19893) and cyclophosphamide (NSC-26271) in the treatment of metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

2 June 2018

A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

20 June 2018

Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Investigating and Dealing with Publication and Other Biases

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Quality of life assessment in patients with hormone-resistant prostate cancer treated with epirubicin or with epirubicin plus medroxy progesterone acetate - is it feasible?

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Phase II study of oxaliplatin versus oxaliplatin combined with infusional 5-fluorouracil in hormone refractory metastatic prostate cancer patients

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Combination of LHRH analog with somatostatin analog and dexamethasone versus chemotherapy in hormone-refractory prostate cancer: a randomized phase II study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. Danish Prostatic Cancer Group.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Phase III study of combined chemohormonal therapy in metastatic prostate cancer (ECOG 3882): an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Liarozole--a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Liarozole Study Group

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-6-112

21 January 2018

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

27 November 2018

Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

27 November 2018

A randomised dose-finding phase II study on ifosfamide in metastatic hormone-refractory prostate cancer (HRPC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

27 November 2018

Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1550253

27 November 2018

[Reducing the side effects of aggressive chemotherapy (cisplatin and epirubicin) with xenogenic peptides (factor AF2) in patients with hormone refractory metastatic prostate cancer. A prospective, randomized study]

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epirubicin and medroxyprogesterone acetate versus estramustine phosphate in hormone-resistant prostatic cancer: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[A randomized trial of chemotherapy of advanced prostatic cancer with ifosfamide alone versus ifosfamide, 5-fluorouracil and cisplatin (preliminary report)]

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of Estramustine Phosphate and Vincristine Alone or in Combination for Patients with Advanced, Hormone Refractory, Previously Irradiated Carcinoma of the Prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: A Hoosier Oncology Group and Fox Chase Network phase III trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone-resistant prostate cancer: a prospective randomized pilot trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: Prognostic factors and response

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A retrospective study of the time to clinical endpoints for advanced prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of estramustine and prednimustine versus prednimustine alone in advanced metastatic prostatic cancer patients who have received prior irradiation

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of estramustine phosphate versus cis-platinum alone versus estramustine phosphate plus cis-platinum in patients with advanced hormone refractory prostate cancer who had had extensive irradiation to the pelvis or lumbosacral area

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with weekly doxorubicin (adriamycin) in hormone-refractory stage D2 prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective, randomized controlled study on the treatment of stage C and stage D prostatic cancer with estracyt in combination with other chemotherapeutic agents

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil in advanced prostatic cancer: a randomized trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/16670021

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2407-6-112

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

Dimensions Publication ID

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28217407&oldid=2177516712"